Eli Lilly and Company (LLY) vs Neurocrine Biosciences, Inc. (NBIX)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| LLY | NBIX | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - Specialty & Generic |
| Size band | MEGA | LARGE |
| Listing | NYSE | Nasdaq GS |
| Country | United States | United States |
| Theme | glp-1-and-obesity | neuroscience |
| Price and returns | ||
| Last close | $1,279.14 | $145.87 |
| Return · 1 week | +3.13% | +6.49% |
| Return · 1 month | +7.96% | +3.87% |
| Return · 3 months | +4.79% | −20.22% |
| Return · year to date | +18.80% | +3.75% |
| Return · 1 year | +55.54% | −2.06% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −3.18% | −21.63% |
| 52-week high | $1,321.21 | $186.12 |
| 52-week low | $793.82 | $122.14 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $1.14T | $14.83B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $2.81B | $170.53M |
| Employees | 50,000 | 2,500 |
| Valuation | ||
| Price to earnings · trailing | 42.75× | 19.90× |
| Price to earnings · forward | 26.97× | 11.36× |
| Price to sales | 14.25× | 4.09× |
| Price to book | 33.51× | 3.73× |
| Enterprise value to EBITDA | 28.32× | 15.18× |
| Enterprise value to revenue | 14.83× | 4.11× |
| PEG ratio | 1.23 | 0.28 |
| Earnings per share · trailing | 29.79 | 6.82 |
| Profitability | ||
| Gross margin | 83.40% | 97.91% |
| Operating margin | 54.22% | 22.19% |
| Profit margin | 33.53% | 20.91% |
| Return on equity | 102.29% | 22.09% |
| Return on assets | 20.36% | 11.70% |
| Growth | ||
| Revenue growth | +47.70% | +39.50% |
| Earnings growth | +26.20% | +31.10% |
| Balance sheet and payout | ||
| Debt / equity (%) | 162.07 | 12.50 |
| Current ratio | 1.36 | 1.87 |
| Dividend yield | 0.54% | 0.00% |
| Payout ratio | 21.69% | 0.00% |
| Trend and volatility | ||
| RSI · 14 | 63.04 | 55.37 |
| ADX · 14 | 31.31 | 22.15 |
| 50-day average | $1,188.58 | $147.30 |
| 200-day average | $1,085.91 | $147.14 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 3.16% | 2.32% |
The full LLY analysis
Everything this table leaves out for Eli Lilly and Company: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the LLY argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full LLY analysisThe full NBIX analysis
Everything this table leaves out for Neurocrine Biosciences, Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the NBIX argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full NBIX analysis